眼内注射康柏西普与雷珠单抗对湿性年龄相关性黄斑变性的疗效  

Efficacy of conbercept and ranibizumab in the treatment of neovascular age-relatedmacular degeneration

作　　者：魏婷 王伟[1] 谢鹏 WEI Ting;WANG Wei;XIE Peng(Department of Ophthalmology,Wanbei Coal and Power Group General Hospital,Suzhou 234000,Anhui,China)

机构地区：[1]皖北煤电集团总医院眼科,安徽宿州234000

出　　处：《川北医学院学报》2021年第4期513-516,共4页Journal of North Sichuan Medical College

摘　　要：目的:探究眼内注射康柏西普与雷珠单抗对湿性年龄相关性黄斑变性(nAMD)疗效。方法:根据患者自行选择药物的意愿,将104例湿性年龄相关性黄斑变性患者分为康柏西普组和雷珠单抗组,每组各52例。比较两组患者治疗总有效率、治疗前后黄斑部外层视网膜管状结构(ORT)发生率、最佳矫正视力(BCVA)、黄斑中心凹厚度(CMT)、黄斑中心凹厚度及中心凹浅层血管密度、黄斑容积、血清C反应蛋白(CRP)及血管内皮生长因子(VEGF)水平;统计两组患者治疗后脉络膜新生血管(CNV)渗漏情况、眼内异物感、一次性眼压过高等并发症发生情况。结果:康柏西普组的治疗总有效率高于雷珠单抗组(P<0.05);治疗后1个月,康柏西普组BCVA值大于雷珠单抗组,CMT及黄斑容积、黄斑中心凹浅层血管密度、ORT发生率、血清CRP及VEGF水平低于雷珠单抗组(P<0.05);两组CNV减少率,3个月后的BCVA、CMT及黄斑中心凹浅层血管密度、黄斑容积及并发症发生率比较,差异均无统计学意义(P>0.05)。结论:康柏西普治疗nAMD的近期疗效高于雷珠单抗,且能提高视力,减少黄斑中心凹视网膜厚度,但随着时间的延长,两者疗效相当。Objective:To explore the efficacy of conbercept and ranibizumab in the treatment of neovascular age-relatedmacular degeneration(nAMD).Methods:A total of 104 nAMD patients were divided into conbercept group(n=52)and ranibizumab group(n=52)according to the willingness of patients to choose drugs.The total response rate of treatment,incidence of outer retinal tubulation(ORT)before and after treatment,best corrected visual acuity(BCVA),central macular thickness(CMT),superficial foveal vascular density and macular volume,levels of serum C-reactive protein(CRP)and vascular endothelial growth factor(VEGF)were compared between the two groups.The choroidal neovascularization(CNV)leakage after treatment,occurrence of complications such as postoperative intraocular foreign body sensation and one-time too high intraocular pressure in both groups was statistically analyzed.Results:The total response rate of treatment in conbercept group was significantly higher than that in ranibizumab group(P<0.05).1 month after treatment,BCVA in conbercept group was obviously greater than that in ranibizumab group,while their CMT and macular volume,superficial macular fovea vascular density,incidence of ORT,levels of serum CRP and VEGF in conbercept group were notably less than those in the ranibizumab group(P<0.05).There were no significant differences in CNV reduction rate,BCVA,CMT,superficial macular fovea vascular density and macular volume 3 months later,and incidence of complications between the two groups(P>0.05).Conclusion:The short-term curative effect of conbercept is better than that of ranibizumab on nAMD,which can improve visual acuity and reduce the CMT.However,as time goes on,curative effect of conbercept and ranibizumab is the same on nAMD.

关 键 词：湿性年龄相关性黄斑变性 康柏西普 雷珠单抗 黄斑中心凹厚度 黄斑部外层视网膜管状结构 视力 

分 类 号：R774.5[医药卫生—眼科]